1. Home
  2. TNK vs IMNM Comparison

TNK vs IMNM Comparison

Compare TNK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teekay Tankers Ltd.

TNK

Teekay Tankers Ltd.

HOLD

Current Price

$76.70

Market Cap

2.9B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$19.97

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNK
IMNM
Founded
2007
2006
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.6B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
TNK
IMNM
Price
$76.70
$19.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$80.00
$32.80
AVG Volume (30 Days)
343.3K
764.8K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
2.55%
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
$8.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.05
$7.83
52 Week High
$83.99
$27.65

Technical Indicators

Market Signals
Indicator
TNK
IMNM
Relative Strength Index (RSI) 47.98 31.70
Support Level $71.94 $19.23
Resistance Level $80.97 $23.24
Average True Range (ATR) 2.93 1.13
MACD -0.60 -0.36
Stochastic Oscillator 16.73 0.00

Price Performance

Historical Comparison
TNK
IMNM

About TNK Teekay Tankers Ltd.

Teekay Tankers Ltd is a provider of marine services to the international oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: Tankers, which consists of the operation of all of the company's tankers (including the operations from those tankers employed on full service lightering contracts), and the company's U.S. based ship-to-ship support service operations (including its lightering support services provided as part of full service lightering operations); and Marine Services, which consists of operational and maintenance marine services provided to the Australian government, Australian energy companies and other third parties. The company generates the majority of its revenue from the Tankers segment.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: